Breaking News, Collaborations & Alliances

AGC Biologics Partners with Quell Therapeutics for Treg Cell Therapy Development

AGC’s ProntoLVV platform to support Quell in advancing Treg cell therapies toward clinical trials.

Author Image

By: Charlie Sternberg

Associate Editor

AGC Biologics, a CDMO expert, has partnered with Quell Therapeutics, a clinical-stage biotechnology company pioneering engineered T-regulatory (Treg) cell therapies, to support the development of multiple Treg cell therapy drug candidates targeting severe immune disorders. AGC Biologics will provide lentiviral vector (LVV) material using its proprietary ProntoLVV platform to prepare these therapies for CTA / IND submissions. Under this agreement, AGC Biologics’ Milan Cell and Gene Center of E...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters